Latest Diagnostics News

Emyria Limited reports sustained clinical success in its PTSD program, launches a new treatment-resistant depression therapy, and opens a second Empax Centre to meet growing demand. The company is progressing funding discussions with health insurers and government bodies to support expansion.

Lumos Diagnostics reported a 21% quarter-on-quarter revenue increase in Q3 FY25, driven by strong product sales and expanded development agreements. The company also secured Medicare coverage in key US regions and advanced its pivotal FebriDx CLIA waiver study with FDA submission expected by year-end.

Enlitic has announced a strategic collaboration with GE HealthCare to deploy AI-driven technology that will transform the migration of medical imaging data, promising faster, more secure transitions and enhanced data quality for healthcare providers worldwide.

Axel REE has engaged SRK Consulting and ANSTO to initiate a maiden Mineral Resource Estimate and metallurgical testing for rare earth elements and gallium at its flagship Caladão Project in Brazil, marking a pivotal step in developing one of the world’s few combined REE and gallium resources.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.

Pro Medicus has delivered a record first half in FY25, driven by strong revenue growth, major contract wins, and successful implementations that position it well for future expansion.

Telix Pharmaceuticals has gained UK MHRA approval for Illuccix, its advanced prostate cancer PET imaging agent, promising to alleviate supply shortages and improve diagnostic accuracy across the UK.

Rewardle Holdings (RXH) confirms plans to lodge delayed financial reports by mid-February 2025, addressing audit complexities linked to its CloudHolter investment and ongoing partnership negotiations.

Artrya has secured a pivotal three-year commercial contract with Sonic Healthcare Australia to deploy its AI-driven Salix Coronary Anatomy platform across over 125 radiology centres, marking a significant step in commercialising its coronary artery disease diagnostic technology.

Echo IQ has secured a $1.26 million refund under the Australian Government's R&D Tax Incentive, reinforcing its commitment to AI-driven solutions for structural heart disease detection.

EMVision Medical Devices has secured US ethics approval for its pivotal multi-centre trial of the EMVision emu™ brain scanner, paving the way for a March 2025 trial start aimed at FDA clearance.